Johnson & Johnson vs Sarepta Therapeutics, Inc. — Stock Comparison

JNJ
Johnson & Johnson
$227.19
▼ 1.16%
vs
SRPT
Sarepta Therapeutics, Inc.
$21.49
▲ 2.92%
Q·Score Winner
Johnson & Johnson
JNJ7.1/10vs 4.4/10

Q·Score Breakdown

7.1
Bullish
Overall
4.4
Bearish
9.3
Quality
1.3
6.5
Health
6.9
5.1
Growth
3.3
7.3
Valuation
6.7
6.5
Sentiment
4.7
JNJ

High-quality business with 26% return on equity and 22% profit margins.

earnings contracting 53% year-over-year.

SRPT

Healthy balance sheet and financial position.

currently unprofitable (-32% margin).

Analyst Consensus

BUY
Target $252.42 (+11.1%)
24 analysts
HOLD
Target $21.78 (+1.4%)
23 analysts

Fundamentals

JNJ
SRPT
26.3×
Trailing P/E
17.9×
Forward P/E
7.2×
21.8%
Profit Margin
-32.5%
68.0%
Gross Margin
-7.4%
26.4%
ROE
-53.5%
9.9%
Revenue Growth
-32.7%
-52.9%
Earnings Growth
0.33
Beta
0.28
Price / Book
$546.9B
Market Cap
$2.3B
$146 – $252
52-Week Range
$10 – $65

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →